In high-income countries people at high risk of TB disease undergo screening programmes even when they have no symptoms.
Articles on World TB Day 2022
Displaying all articles
In 2020 TB case detection fell by almost 20% and mortality rose for the first time in a decade. These setbacks are directly attributable to the COVID-19 pandemic.
Manufacturers and health systems have shown that vaccines can be quickly and effectively deployed when accompanied by keen political and financial commitments.
This challenges the current assumption that coughing is the primary driver of TB transmission.
Progress against tuberculosis has long been inadequate to reach the target of elimination by 2030. But before the COVID-19 pandemic the world was making steady progress in diagnosing and treating TB.
BCG remains the only widely available vaccine for TB. Yet the development of a COVID-19 vaccine over the last year shows that there is capacity to rapidly create new vaccines.
Top contributors
-
Assistant Professor, Africa Health Research Institute (AHRI)
-
Assistant Professor in Health Economics, London School of Hygiene & Tropical Medicine
-
PhD Candidate, University of Cape Town
-
Professor of International Health at LSHTM and Member of Faculty, Africa Health Research Institute (AHRI)
-
Assistant Professor, Infectious Disease Epidemiology , London School of Hygiene & Tropical Medicine
-
PhD candidate, Africa Health Research Institute (AHRI)
-
Head of the Centre of Excellence for Biomedical TB Research, University of the Witwatersrand
-
Faculty Member, Africa Health Research Institute; Wellcome Trust Senior Research Fellow, UCL
-
Director, Center for Tuberculosis Research, Johns Hopkins University
-
Professor of Medicine, College of Health Sciences, Makerere University
-
Research fellow, clinical research at London School of Hygiene and Tropical Medicine, Africa Health Research Institute (AHRI)